UK facial biometric firm iProov chosen to help US Department of Homeland Security to enhance and secure cross-border passenger travel
iProov, a leading provider of biometric facial verification technology, today announced it has become the first British – and indeed overseas – company to be awarded a contract from the US Department of Homeland Security Science & Technology Directorate’s Silicon Valley Innovation Program (SVIP).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180416006084/en/
iProov CEO, Andrew Bud (Photo: Business Wire)
The contract has been awarded to iProov to help US Customs and Border Protection (CBP) improve the passenger entry operation process.
London-based iProov was founded in 2011 by CEO Andrew Bud. The company’s facial biometric technology, patented in the US and UK, is used by banks and governments around the world for secure customer onboarding, logon and authentication, to ensure new and returning users are genuine and guard against fraudulent attempts to gain access to personal data or use a stolen identity.
The contract iProov has won will see the company develop technology that aims to enhance cross-border passenger travel at unmanned ports of entries while reducing processing time. It could help US CBP quickly, accurately and reliably identify travellers as they process through US border crossings.
At the heart of this announcement is iProov’s Flashmark technology, deployed in its secure, cloud-based facial biometric verification system that can be accessed via a user’s mobile phone. In this case, iProov’s technology will work with existing CBP systems, on which travellers’ details are pre-registered. In the run up to arrival at the US border, whether at home or en route, travellers would be able to self-serve the document check that normally happens at the point of border crossing, by authenticating themselves securely to their pre-registered photo, via their mobile phone. The process is simple, much quicker than waiting in line, and more secure than traditional methods.
Dr. Liam Fox, Secretary of State for the UK Department for International Trade, commented, “The UK and US are world leaders in cyber security. Through close cooperation across various sectors, trade between the two countries has grown to £181.2 billion pounds in 2017 - making the US our largest trading partner and biggest export market.
“One example of our shared economic and security ties is UK based iProov technology, which uses cutting-edge facial biometric verification technology to enhance security and deter those who seek to cause harm. It is now used by a range of institutions across the world and will soon be used by the US Customs and Border Protection, helping to enhance the way it processes people through US borders.”
The reason iProov was selected comes down to its ability to detect ‘spoofs’. In a self-serve identity verification environment, the system must be able to confirm whether or not the person presenting themselves for verification is genuinely the owner of the ID credential, not a photo, screen image or doctored video. iProov has ten granted patents in the UK and US for the technology that can detect these spoofs, and in this way is uniquely able to help governments tackle the pressure they are under from increased traveller numbers to swiftly but securely verify each and every traveller.
It is this growth in international travel which led the DHS S&T Directorate’s SVIP to look for partners to help tackle the cross-border passenger entry operation process. Over 112 million passengers enter the United States annually and over 1 million attempt to pass through its borders each day, increasing the pressure on Customs and Border Protection to facilitate the entry of international visitors, increase tourism and foster economic growth while ensuring the highest level of security.
iProov’s CEO, Andrew Bud, who will be speaking about the contract win while part of a UK trade delegation with the UK’s Department for International Trade to global cyber security conference RSA in San Francisco, commented, “We are delighted that iProov has been selected by the US Department of Homeland Security to enhance the way in which it processes people through US borders. Advances in machine learning and AI have enabled a revolution in facial biometrics in the last few years and we’re now seeing more and more cases of governments and banks turning to self-service, spoof-resilient face verification as the biometric of choice to both increase security and ensure ease of use.”
This is not the first time iProov has been recognised for its industry leading identity verification technology. The company won the 2017 National Cyber Security Centre’s Cyber Dragon’s Den competition at CYBERUK 2017; it has received a number of grants from Innovate UK, the UK's innovation agency; and in September 2017 was named the sole UK member of the SINET16, a select group of cyber-security innovators. In the financial services sector its technology is in live use with banks such as DNB in Norway and Rabobank in the Netherlands.
Founded in 2011 by CEO Andrew Bud, iProov is a world leader in spoof-resistant, biometric facial verification technology. Its technology is used by banks and governments around the world for secure customer onboarding, logon and authentication, to ensure new and returning users are genuine and guard against fraudulent attempts to gain access to personal data or use a stolen identity. For more information, please see www.iproov.com
+44 7833 474 447
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
First Westinghouse AP1000® Nuclear Plant Sanmen 1 Completes Initial Criticality21.6.2018 23:24 | Tiedote
Westinghouse Electric Company, China State Nuclear Power Technology Corporation (SNPTC) announced today that the world’s first AP1000 nuclear power plant located in Sanmen, Zhejiang Province, China has successfully completed initial criticality. “Today we completed the final major milestone before commercial operation for Westinghouse’s AP1000 nuclear power plant technology,” said José Emeterio Gutiérrez, Westinghouse president and chief executive officer. “We are one step closer to delivering the world’s first AP1000 plant to our customer and the world – with our customers, we will provide our customers in China with safe, reliable and clean energy from Sanmen 1.” Following initial criticality will be connection to the electrical grid. Once plant operations begin at Sanmen 1, it will be the first AP1000 nuclear power plant in operation, offering innovative passive safety system technology, multiple layers of defense and advanced controls for unequaled reliability and safety. Commentin
Westinghouse Loads Fuel in Second AP1000® Nuclear Power Plant21.6.2018 23:07 | Tiedote
Westinghouse Electric Company and its customers, China State Nuclear Power Technology Corporation (SNPTC) and Shangdong Nuclear Power Company Limited (SDNPC) announced today that Haiyang Unit 1, the AP1000 nuclear power plant located in Haiyang, Shandong Province, China, has begun to load fuel. “This is a great day for Westinghouse, our China partners and the nuclear industry. Haiyang Unit 1 continues to demonstrate our ability to deliver safe, innovative solutions for power generation,” said José Emeterio Gutiérrez, Westinghouse president and chief executive officer. He added, “Westinghouse will continue to deploy AP1000 technology throughout the world and demonstrate our technical leadership in the nuclear energy industry.” Fuel load at Haiyang Unit 1 commenced at 7:36 p.m. (GMT+8) today. Earlier this summer, in preparation for fuel load, Haiyang Unit 1 successfully completed the necessary testing and regulatory reviews conducted by China’s National Nuclear Safety Administration (NNS
Pharnext to Announce Top-Line Results from the Pivotal Phase 3 Trial of PXT3003 for the Treatment of Charcot-Marie-Tooth Type 1A Disease by October 201821.6.2018 21:23 | Tiedote
Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced an update from its ongoing Phase 3 clinical program (PLEO-CMT and PLEO-CMT-FU studies) evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A) in adults. Top-line results from the pivotal PLEO-CMT study are now expected by October 2018. Prof. Daniel Cohen, M.D., Ph.D., Pharnext’s Co-Founder and Chief Executive Officer said: “We are thrilled to bring this Phase 3 clinical trial to completion and we now expect to disclose top-line results by October of this year. Our PLEODRUG™ PXT3003 has already shown initial signals of efficacy in our Phase 2 trial in CMT1A. We are hopeful we can bring this much-needed therapy to patients suffering from this debilitating condition, as they currently have limited therapeutic options, mo
Philip Morris International Makes Call to Creative, Media and Communications Communities21.6.2018 21:13 | Tiedote
Philip Morris International Inc. (“PMI”) (NYSE: PM), today announced a bold call to action for the creative, media and communications communities to embrace its ongoing commitment to creating a smoke-free world. As part of this initiative, PMI will offer smoke-free alternatives wherever we can, including heated tobacco products and e-cigarettes, to current smokers in the industry who would otherwise continue to smoke. During a keynote at the PMI Science Lounge at The Cannes Festival of Creativity, SVP of Communications Marian Salzman said, “We are asking the creative community to join us in raising awareness of the potential of science, technology and innovation for those who smoke and the people around them.” The move is part of PMI’s vision to lead the charge towards greater innovation and technology in the tobacco industry, all of which is backed by science. Agencies interested in joining the movement can contact Marian Salzman at firstname.lastname@example.org. “People who smoke deserve in
IBC2018 Announces Cyber Security Forum to Help Media Tackle Cyber Threats21.6.2018 19:30 | Tiedote
IBC2018, the world’s most influential media, entertainment and technology show, today announces a Cyber Security Forum to expand its position as the preeminent cyber security destination for broadcasters and media. The event will form part of the prestigious annual IBC show at the RAI in Amsterdam from Thursday 13 to Tuesday 18 September 2018, which last year attracted more than 57,000 attendees from 170 countries. The Cyber Security Forum is one-day, invitation-only event that will convene Chief Technology Officers, Chief Information Officers, Chief Information Security Officers and Chief Digital Officers within media and broadcasting for a conversation on the challenges and opportunities presented by cyber security for broadcasters. Attendees will discuss how to anticipate the next cyber threat, how to manage a breach and how to prepare for the future of cyber security. The Cyber Security Forum sits alongside the Telco & Media Innovation Forum and Leaders’ Forum as part of IBC’s Exec
Mensia Technologies Raises 1,3 Million Euro to Introduce Koala Neurofeedback as a Revolutionary Medical Device in Europe21.6.2018 19:23 | Tiedote
Mensia Technologies, french MedTech start up, leads the new booming category of Digital therapeutics with its revolutionary « at home « neurofeedback, to train the brain and cure neuropsy disorders without drugs. Co-founder INRIA-IT2, existing shareholders and now HARA, which are business angels experts in medical device category, joined this fund raise. BPI de Rennes is also part of this tour. Mensia Technologies, borned out of INRIA in 2012. The IT expert labs in Rennes are computing real time signaling softwares. The neurofeedback technique is non invasive, at home and without drugs. MENSIA KOALA treats ADHD, Attention Deficit Disorders with or without Hyperactivity, children and adolescents. This unique medical device is a therapeutic video game on an interactive tablet connected to the brain activity. Children learn to control their attention by exercising 3 times a week during 4 months of treatment. Visual feedback given during the game, allows the children to learn, control and
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme